Skip to main content
Home / Resources / On-Demand Webinar / Model-based DDI Extrapolation Strategy from Adults to Children – A Case Study with Risdiplam

Model-based DDI Extrapolation Strategy from Adults to Children – A Case Study with Risdiplam

November 18, 2021
On-Demand Webinar
YouTube video

Risdiplam (EVRYSDI) is approved for the treatment of patients with spinal muscular atrophy ≥ 2 months old. CYP3A-mediated DDI risk in pediatric patients was evaluated by physiologically-based pharmacokinetic (PBPK) modelling and informed the label.

This talk illustrated a modeling strategy for the extrapolation of DDIs from adults to children covering:

  • Development of a patient-specific growth model
  • Validation of the adult PBPK model with independent data
  • Estimation of drug specific DDI parameters from clinical data in healthy adults 
  • Sensitivity assessments of different ontogeny functions for DDI extrapolations from adults to children
  • Approach to qualify DDI prediction in children